ABSTRACT
The role of F-18 fluorodeoxyglucose positron emission tomography/computerized tomography in the treatment follow-up and its differences from adult malignancies were specified in neuroblastoma, lymphoproliferative malignancies, bone and soft tissue sarcomas, which are the most common childhood malignancies. In this review, the elements that need special attention for pediatric patients are highlighted. The strengths of the examination in the aforementioned malignancies and the use of indices and scores in guiding treatment are discussed.
References
1Samim A, Tytgat GAM, Bleeker G, et al. Nuclear Medicine Imaging in Neuroblastoma: Current Status and New Developments J Pers Med 2021;11:270.
2Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-1477.
3Aboian MS, Huang SY, Hernandez-Pampaloni M, et al. 124I-MIBG PET/CT to Monitor Metastatic Disease in Children with Relapsed Neuroblastoma. J Nucl Med 2021;62:43-47.
4Beijst C, de Keizer B, Lam MGEH, Janssens GO, Tytgat GAM, de Jong HWAM. A phantom study: Should 124 I-mIBG PET/CT replace 123 I-mIBG SPECT/CT? Med Phys 2017;44:1624-1631.
5Lee CL, Wahnishe H, Sayre GA, et al. Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET. Med Phys 2010;37:4861-4867.
6Lewington V, Lambert B, Poetschger U, et al. 123I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting,method by an international panel. Eur J Nucl Med Mol Imaging 2017;44:234-241.
7Yanik GA, Parisi MT, Naranjo A, et al. Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children’s Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1. J Nucl Med 2018;59:502-508.
8Bar-Sever Z, Biassoni L, Shulkin B, et al. Guidelines on nuclear medicine imaging in neuroblastoma. Eur J Nucl Med Mol Imaging 2018;45:2009-2024.
9Kushner BH, Yeung HW, Larson SM, Kramer K, Cheung NK. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol 2001;19:3397-3405.
10Abongwa C, Mott S, Schafer B, et al. Safety and accuracy of 68Ga-DOTATOC PET/CT in children and young adults with solid tumors. Am J Nucl Med Mol Imaging 2017;7:228-235.
11Gains JE, Aldridge MD, Mattoli MV, et al. 68Ga-DOTATATE and 123I-mIBG as imaging biomarkers of disease localisation in metastatic neuroblastoma: implications for molecular radiotherapy. Nucl Med Commun 2020;41:1169-1177.
12Gains JE, Moroz V, Aldridge MD, et al. A phase IIa trial of molecular radiotherapy with 177-lutetium DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma. Eur J Nucl Med Mol Imaging 2020;47:2348-2357.
13Piccardo A, Morana G, Puntoni M, et al. Diagnosis, Treatment Response, and Prognosis: The Role of 18F-DOPA PET/CT in Children Affected by Neuroblastoma in Comparison with 123I-mIBG Scan: The First Prospective Study. J Nucl Med 2020;61:367-374.
14Zhang H, Huang R, Cheung NK, et al. Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG. Clin Cancer Res 2014;20:2182-2191.
15Sedig LK, Bailey JJ, Wong KK, Brown RKJ, Kaminski MS, Hutchinson RJ. Do Deauville Scores Improve the Clinical Utility of End-of-Therapy FDG PET Scans for Pediatric Hodgkin Lymphoma? AJR Am J Roentgenol 2019;212:456-460.
16Charpentier AM, Friedman DL, Wolden S, et al. Predictive Factor Analysis of Response-Adapted Radiation Therapy for Chemotherapy-Sensitive Pediatric Hodgkin Lymphoma: Analysis of the Children’s Oncology Group AHOD 0031 Trial. Int J Radiat Oncol Biol Phys 2016;96:943-950.
17Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32:3059-3068.
18Qiu L, Chen Y, Wu J. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin’s lymphoma and non-Hodgkin’s lymphoma. Hell J Nucl Med 2013;16:230-236.
19Brink I, Reinhardt MJ, Hoegerle S, Altehoefer C, Moser E, Nitzsche EU. Increased metabolic activity in the thymus gland studied with 18F-FDG PET: age dependency and frequency after chemotherapy. J Nucl Med 2001;42:591-595.
20Vali R, Alessio A, Balza R, et al. SNMMI Procedure Standard/EANM Practice Guideline on Pediatric 18F-FDG PET/CT for Oncology 1.0. J Nucl Med 2021;62:99-110.
21Cousins J, Czachowski M, Muthukrishnan A, Currie G. Pediatric Brown Adipose Tissue on 18F-FDG PET: Diazepam Intervention. J Nucl Med Technol 2017;45:82-86.
22Williams G, Kolodny GM. Method for decreasing uptake of 18F-FDG by hypermetabolic brown adipose tissue on PET. AJR Am J Roentgenol 2008;190:1406-1409.
23Arush MW, Israel O, Postovsky S, et al. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma. Pediatr Blood Cancer 2007;49:901-905.
24Franzius C, Sciuk J, Daldrup-Link HE, Jürgens H, Schober O. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur J Nucl Med 2000;27:1305-1311.
25Ruggiero A, Lanni V, Librizzi A, et al. Diagnostic Accuracy of 18F-FDG PET/CT in the Staging and Assessment of Response to Chemotherapy in Children With Ewing Sarcoma. J Pediatr Hematol Oncol 2018;40:277-284.
26Salem U, Amini B, Chuang HH, et al. 18F-FDG PET/CT as an Indicator of Survival in Ewing Sarcoma of Bone. J Cancer 2017;8:2892-2898.
27Raciborska A, Bilska K, Drabko K, et al. Response to chemotherapy estimates by FDG PET is an important prognostic factor in patients with Ewing sarcoma. Clin Transl Oncol 2016;18:189-195.
28Cistaro A, Lopci E, Gastaldo L, Fania P, Brach Del Prever A, Fagioli F. The role of 18F-FDG PET/CT in the metabolic characterization of lung nodules in pediatric patients with bone sarcoma. Pediatr Blood Cancer 2012;59:1206-1210.
29Kong CB, Byun BH, Lim I, et al. ¹⁸F-FDG PET SUVmax as an indicator of histopathologic response after neoadjuvant chemotherapy in extremity osteosarcoma. Eur J Nucl Med Mol Imaging 2013;40:728-736.
30Davis JC, Daw NC, Navid F, et al. 18F-FDG Uptake During Early Adjuvant Chemotherapy Predicts Histologic Response in Pediatric and Young Adult Patients with Osteosarcoma. J Nucl Med 2018;59:25-30.
31Byun BH, Kong CB, Lim I, et al. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma. J Nucl Med 2013;54:1053-1059.
32Im HJ, Zhang Y, Wu H, et al. Prognostic Value of Metabolic and Volumetric Parameters of FDG PET in Pediatric Osteosarcoma: A Hypothesis-generating Study. Radiology 2018;287:303-312.
33Harrison DJ, Chi YY, Tian J, et al. Metabolic response as assessed by 18 F-fluorodeoxyglucose positron emission tomography-computed tomography does not predict outcome in patients with intermediate- or high-risk rhabdomyosarcoma: A report from the Children’s Oncology Group Soft Tissue Sarcoma Committee. Cancer Med 2021;10:857-866.
34Norman G, Fayter D, Lewis-Light K, et al. An emerging evidence base for PET-CT in the management of childhood rhabdomyosarcoma: systematic review. BMJ Open 2015;5:e006030.
35Gennaro N, Marrari A, Renne SL, et al. Multimodality imaging of adult rhabdomyosarcoma: the added value of hybrid imaging. Br J Radiol 2020;93:20200250.
